Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines
as the first-line option for the treatment of venous thromboembolism and prevention of stroke …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

Direct oral anticoagulants (DOACs), direct inhibitors of thrombin or factor Xa (FXa), are
increasingly used in clinical practice for the prevention of thromboembolic complications in …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Aims Observational studies have investigated the effectiveness and safety of direct oral
anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Purpose We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …

Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …